Moodiness, Anxiety, Depression – Sometimes associated with Tamoxifen use, but often these problems arise just from the fact that you are going through cancer. It’s better not to ignore them and I recommend getting some counseling. Meditation is extremely helpful for anxiety and moodiness. For depression related to Tamoxifen, check with your doctor to see if you can reduce your dosage of Tamoxifen. Some women are taking it every other day, rather than daily, and still getting good results. Dietary assistance for these problems includes eating lots of fresh organic veggies and fruit, omega 3 fatty acids, and vitamin B complex – all of these are surprisingly beneficial. One last word about depression – it can come on slowly over a period of several months, and some women will not realize that they are depressed. Pay close attention to this please and get some help if you need it. You may want to discontinue the use of Tamoxifen if the symptoms are severe (discuss this with your doctor). I would not recommend the use of anti-depressants because they may make Tamoxifen less effective.
In a multi-center, double-blind, phase III study, Brown et al (2009) compared the safety and effectiveness of denosumab with alendronate in post-menopausal women with low bone mass. A total of 1,189 post-menopausal women with a T-score less than or equal to - at the lumbar spine or total hip were randomized 1:1 to receive subcutaneous denosumab injections (60 mg every 6 months [Q6M]) plus oral placebo weekly (n = 594) or oral alendronate weekly (70 mg) plus subcutaneous placebo injections Q6M (n = 595). Changes in BMD were assessed at the total hip, femoral neck, trochanter, lumbar spine, and one-third radius at 6 and 12 months and in BTMs at months 1, 3, 6, 9, and 12. Safety was evaluated by monitoring AEs and laboratory values. At the total hip, denosumab significantly increased BMD compared with alendronate at month 12 ( % versus %; p < ). Furthermore, significantly greater increases in BMD were observed with denosumab treatment at all measured skeletal sites (12-month treatment difference: %, femoral neck; %, trochanter; %, lumbar spine; %, one-third radius; p < or = all sites). Denosumab treatment led to significantly greater reduction of BTMs compared with alendronate therapy. Laboratory values and AEs were similar for denosumab- and alendronate-treated subjects. The authors concluded that denosumab showed significantly larger gains in BMD and greater reduction in BTMs compared with alendronate. The overall safety profile was similar for both treatments.
Oral administration of Anastrozole to female rats (from 2 weeks before mating to pregnancy day 7) produced significant incidence of infertility and reduced numbers of viable pregnancies at 1 mg/kg/day (about 10 times the recommended human dose on a mg/m 2 basis and 9 times higher than the AUC 0-24 hr found in postmenopausal volunteers at the recommended dose). Pre-implantation loss of ova or fetus was increased at doses equal to or greater than mg/kg/day (about one-fifth the recommended human dose on a mg/m 2 basis). Recovery of fertility was observed following a 5-week non-dosing period which followed 3 weeks of dosing. It is not known whether these effects observed in female rats are indicative of impaired fertility in humans.